{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/corticosteroids-oral/management/corticosteroids/","result":{"pageContext":{"chapter":{"id":"84dd471a-9a74-5be7-b888-438a149d76de","slug":"corticosteroids","fullItemName":"Scenario: Corticosteroids","depth":2,"htmlHeader":"<!-- begin field 9dc0a534-9b78-41f8-9f4e-e339f19bb935 --><h2>Scenario: Corticosteroids</h2><!-- end field 9dc0a534-9b78-41f8-9f4e-e339f19bb935 -->","summary":"Covers the management of people receiving oral corticosteroids in primary care.","htmlStringContent":"<!-- begin item c42d9379-d479-44b7-a53c-61928d93dfab --><!-- begin field 5219537a-ab69-484c-b1d1-acd900ae04cb --><p>From birth onwards.</p><!-- end field 5219537a-ab69-484c-b1d1-acd900ae04cb --><!-- end item c42d9379-d479-44b7-a53c-61928d93dfab -->","topic":{"id":"2ddb5306-0521-5967-b3ad-e150e92dd71e","topicId":"72c594bc-4c91-4d24-acdb-dda9812ea656","topicName":"Corticosteroids - oral","slug":"corticosteroids-oral","lastRevised":"Last revised in June 2020","chapters":[{"id":"de758570-b276-5b9a-b679-243ca11b5b0b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5db581e9-0a76-58c3-9dc7-3d70e2258a58","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"083ae2c1-9fcd-56d9-9391-3b874be632d6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0863d2e0-89c0-59ea-8c15-e1b41fbd8d5d","slug":"changes","fullItemName":"Changes"},{"id":"1684d913-6ee4-5c81-b8f5-da290e6b10d2","slug":"update","fullItemName":"Update"}]},{"id":"e478b1f3-4d1b-57d5-879f-ad9022a2ec8f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d57df389-307f-59f5-a5e5-f223861afaba","slug":"goals","fullItemName":"Goals"},{"id":"70adac45-ee10-56f9-b88b-e75007cba584","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"fe005751-eb99-5634-a99d-041d841fd184","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"854fdd1a-f9cd-5b0f-95b0-ce2693d04cc8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"03f7459a-9d10-5435-af19-3cb0a39f0a88","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7c4a3b4a-3bfd-5b18-b16c-3350018754f3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"c243f116-7197-5797-8dea-f74bd970f4d7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f776021e-e349-55a4-b655-4801dd7df8e5","slug":"definition","fullItemName":"Definition"},{"id":"241b5d44-7190-5d40-a453-c34255ed8c09","slug":"properties-of-corticosteroids","fullItemName":"Properties of corticosteroids"},{"id":"7cede1e7-70ca-59b2-a0b2-9da96d75e581","slug":"types-of-oral-corticosteroids","fullItemName":"Types of oral corticosteroids"},{"id":"00d48a00-08ac-5b67-a81d-79c587633318","slug":"equivalent-anti-inflammatory-doses","fullItemName":"Equivalent anti-inflammatory doses"}]},{"id":"2d718114-cca8-5be3-9f3b-cd6855079736","fullItemName":"Management","slug":"management","subChapters":[{"id":"84dd471a-9a74-5be7-b888-438a149d76de","slug":"corticosteroids","fullItemName":"Scenario: Corticosteroids"}]},{"id":"6e288e6d-366d-5598-be63-4261ab6000a9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"cd130a7b-8ddf-543d-a4d2-e2b78c7ebe73","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"3b37794e-a5f1-56b1-a7e0-230805f097a3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e3c6ec19-1d84-510b-b44b-43ccb32f6b86","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"60803b59-24a4-5036-b82f-40d837e8e318","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"28cc6229-02b0-596c-b492-3dd868d5230b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7f63de84-1b36-5a2e-b3b3-626df702ff90","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"69d4244b-043f-55e0-80ac-64b46fe11694","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2d718114-cca8-5be3-9f3b-cd6855079736","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"82cce95d-ad78-5d71-a911-6ebce09dd2a4","slug":"initiation","fullItemName":"Initiation","depth":3,"htmlHeader":"<!-- begin field 14594765-6af7-4313-9e0c-fea97cbd529d --><h3>What should I consider when initiating oral corticosteroids?</h3><!-- end field 14594765-6af7-4313-9e0c-fea97cbd529d -->","summary":null,"htmlStringContent":"<!-- begin item 3f5490ff-5d05-4f6e-8ede-cdc6a2f05a1a --><!-- begin field f8a73f0f-cd73-4b1f-8fe2-50f175bf9333 --><ul><li>When initiating oral corticosteroids, take into account the person's individual risk factors for adverse effects, including: <br><ul><li><strong>Age </strong>— children and older people are more susceptible to the <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#adverse-effects\">adverse effects</a> of corticosteroids. </li><li><strong>Medical history</strong> — oral corticosteroids are <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#contraindications-cautions\">contraindicated</a> in people with an untreated systemic infection, and should be used <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#contraindications-cautions\">cautiously</a> (and with very close <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#monitoring\">monitoring</a>) in people with other conditions (such as diabetes mellitus, hypertension, and hepatic impairment).<ul><li>For more information on the baseline measures required before initiating oral corticosteroids and the ongoing monitoring required, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#monitoring\">monitoring</a>.</li></ul></li><li><strong>Concurrent medication</strong> — see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#drug-interactions\">Drug interactions</a> for more information. </li><li><strong>Immunization history</strong> — people who are not up to date with vaccinations should receive them before starting corticosteroid treatment. </li></ul></li><li>Also consider:<ul><li><strong>The condition being treated</strong> — different oral corticosteroids have varying ratios of mineralocorticoid to glucocorticoid properties, and these ratios determine their potency, efficacy, and therapeutic use.</li><li><strong>The dose and duration of treatment</strong> — this influences the incidence and severity of adverse effects. </li><li><strong>Whether the person is <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#pregnancy-breastfeeding\">pregnant or breastfeeding</a>. </strong></li></ul></li><li>For a comparison of the properties and general therapeutic indications of different oral corticosteroids, see Table 2.</li></ul><p><strong>Table 2.</strong> Properties and therapeutic indications of oral corticosteroids, relative to hydrocortisone.</p><table data-table-id=\"85258d57-5cc3-4405-a953-acce014f1a77\"><thead><tr><th>Drug</th><th>Glucocorticoid properties</th><th>Mineralocorticoid properties</th><th>Duration of action after oral dose*</th><th>General therapeutic indication</th></tr></thead><tbody><tr><td>Hydrocortisone </td><td>1</td><td>1</td><td>Short </td><td>Drug of choice for corticosteroid replacement therapy. </td></tr><tr><td>Cortisone </td><td>0.8</td><td>0.8</td><td>Short</td><td>Similar to hydrocortisone, not used as an anti-inflammatory because of mineralocorticoid effects.</td></tr><tr><td>Prednisolone </td><td>4</td><td>0.8</td><td>Intermediate</td><td>Drug of choice for anti-inflammatory and immunosuppressive effects.</td></tr><tr><td>Methylprednisolone</td><td>5</td><td>Minimal</td><td>Intermediate</td><td>Anti-inflammatory and immunosuppressive.</td></tr><tr><td>Deflazacort</td><td>3</td><td>Minimal</td><td>Short</td><td>Similar to prednisolone.</td></tr><tr><td>Dexamethasone </td><td>27</td><td>Minimal </td><td>Long</td><td>Anti-inflammatory and immunosuppressive, used especially when water retention is undesirable (e.g. cerebral oedema) as it has little, if any, mineralocorticoid activity. Long duration of action makes it useful in conditions such as congenital adrenal hyperplasia.</td></tr><tr><td>Betamethasone </td><td>27</td><td>Negligible</td><td>Long</td><td>Anti-inflammatory and immunosuppressive, used especially when water retention is undesirable as it has little, if any, mineralocorticoid activity. Long duration of action makes it useful in conditions such as congenital adrenal hyperplasia.</td></tr><tr><td>Fludrocortisone</td><td>15</td><td>150</td><td>Short</td><td>Drug of choice for mineralocorticoid effects (for example, in orthostatic hypotension).</td></tr><tr><td colspan=\"5\">*Short, half-life 8–12 hours; intermediate, half-life 18–36 hours; long, half-life 36–54 hours.</td></tr><tr><td colspan=\"5\">Data from [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Brayfield, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Ritter, 2020</a>]</td></tr></tbody></table><!-- end field f8a73f0f-cd73-4b1f-8fe2-50f175bf9333 --><!-- end item 3f5490ff-5d05-4f6e-8ede-cdc6a2f05a1a -->","subChapters":[{"id":"82e3163c-25b9-5bea-9c2d-399f05090b54","slug":"basis-for-recommendation-7ef","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field bffe0a24-c8d7-4706-b294-502c7d0781cb --><h4>Basis for recommendation</h4><!-- end field bffe0a24-c8d7-4706-b294-502c7d0781cb -->","summary":null,"htmlStringContent":"<!-- begin item 7ef7d00f-8751-428e-a35d-65f3640af1d6 --><!-- begin field cade2e7e-7576-4fc0-9830-80a494b861a3 --><p>These recommendations are based on expert opinion in the textbooks <em>Rang and Dale's Pharmacology</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Ritter, 2020</a>] and <em>Meyler's side effects of endocrine and metabolic drugs</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Aronson, 2009</a>], the <em>British National Formulary</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Joint Formulary Committee, 2020</a>], a drug reference compendium <em>Martindale: the complete drug reference</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Brayfield, 2020</a>], expert opinion in a narrative review <em>Prevention and management of glucocorticoid-induced side effects: a comprehensive review. Infectious complications and vaccination recommendations</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Caplan, 2017a</a>], and what CKS considers good clinical practice.</p><ul><li>Prolonged use of glucocorticoids in older people can exacerbate conditions such as hypertension, diabetes mellitus, heart failure, and osteoporosis. They can also cause depression [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Aronson, 2009</a>].</li><li>Children may be at increased risk of some adverse effects (for example growth suppression) and prolonged use is rarely justified [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Brayfield, 2020</a>].</li><li>Patients who are not up to date on vaccinations should receive them before starting corticosteroids, if possible, so that an appropriate protective immune response may occur [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Caplan, 2017a</a>].</li></ul><!-- end field cade2e7e-7576-4fc0-9830-80a494b861a3 --><!-- end item 7ef7d00f-8751-428e-a35d-65f3640af1d6 -->","subChapters":[]}]},{"id":"8a353827-ba65-5ef0-add3-2e9baa2e3814","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 8b009cd5-8dc7-4ecd-b157-4bc130b772e3 --><h3>What contraindications and cautions are associated with oral corticosteroids?</h3><!-- end field 8b009cd5-8dc7-4ecd-b157-4bc130b772e3 -->","summary":null,"htmlStringContent":"<!-- begin item d7762b22-3fe6-40e6-a920-4a360148c1b6 --><!-- begin field ff4fa706-5a4a-4c10-a9c9-abd75e5ff1bd --><ul><li><strong>Oral corticosteroids are contraindicated in:</strong><ul><li><strong>People with acute infections uncontrolled by appropriate antimicrobial therapy</strong> — they may mask the symptoms of infection.</li></ul></li><li><strong>Oral corticosteroids should be used with caution in people with:</strong><br><ul><li><strong>Hepatic impairment </strong>— plasma concentrations of oral corticosteroids may be increased in hepatic impairment. </li><li><strong>Psychoses or severe affective disorders (or a family history of psychiatric disorders) </strong>— potentially serious mental disorders may occur during treatment with corticosteroids, and existing emotional instability and psychotic tendencies can also be exacerbated. Advise people to seek medical advice if psychiatric symptoms (especially depression and suicidal thoughts) occur and to be alert to the rare possibility of such reactions during withdrawal of corticosteroid treatment.</li><li><strong>Wounds </strong>— avoid corticosteroids in people with wounds that require repair and healing, or use cautiously if this is unavoidable.</li><li><strong>Systemic sclerosis</strong> — caution is required due to an increased incidence of (possibly fatal) scleroderma renal crisis with hypertension and decreased urinary output. This has been observed with a daily dose of 15 mg or more of prednisolone.</li><li><strong>Other pre-existing conditions, including: </strong><ul><li>Congestive heart failure.</li><li>Diabetes mellitus, including a family history of diabetes mellitus.</li><li>Diverticulitis.</li><li>Epilepsy.</li><li>Glaucoma, or a family history or susceptibility to glaucoma.</li><li>History of tuberculosis or X-ray changes characteristic of tuberculosis – frequent monitoring is required.</li><li>Hypertension.</li><li>Hypothyroidism.</li><li>Myasthenia gravis.</li><li>Ocular herpes simplex – risk of corneal perforation. </li><li>Osteoporosis.</li><li>Peptic ulcer.</li><li>Recent intestinal anastomosis.</li><li>Recent myocardial infarction.</li><li>Renal impairment.</li><li>Thromboembolic disorders.</li><li>Ulcerative colitis. </li><li>A history of steroid myopathy.</li></ul></li></ul></li><li>Administration of live vaccines is contraindicated in people receiving immunosuppressive doses of corticosteroids.</li></ul><!-- end field ff4fa706-5a4a-4c10-a9c9-abd75e5ff1bd --><!-- end item d7762b22-3fe6-40e6-a920-4a360148c1b6 -->","subChapters":[{"id":"b3a72ce7-bdd7-53b6-859a-62671ff90671","slug":"basis-for-recommendation-6fc","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 3a41b799-4a62-44bd-8e09-c05ee72fc70b --><h4>Basis for recommendation</h4><!-- end field 3a41b799-4a62-44bd-8e09-c05ee72fc70b -->","summary":null,"htmlStringContent":"<!-- begin item 6fc95ba9-cf03-4f33-9fed-7e8cdff16faa --><!-- begin field 46b4fa24-2c24-4703-8262-62738dd43eb7 --><p>These recommendations are based on the textbook <em>Meyler's side effects of endocrine and metabolic drugs</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Aronson, 2009</a>], the <em>British National Formulary</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Joint Formulary Committee, 2020</a>], a drug reference compendium <em>Martindale: the complete drug reference</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Brayfield, 2020</a>], and the manufacturer's Summary of Product Characteristics for prednisolone tablets [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">ABPI, 2020</a>]. </p><h5>Cautions</h5><ul><li>The recommendation that corticosteroids should be used with caution in people with hepatic impairment is based on the <em><em>British National Formulary</em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Joint Formulary Committee, 2020</a>], the manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">ABPI, 2020</a>], <em>Martindale: the complete drug reference </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Brayfield, 2020</a>], and <em>Meyler's side effects of endocrine and metabolic drugs </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Aronson, 2009</a>].  <ul><li>In people with acute hepatitis, protein binding of glucocorticoids is reduced and peak concentration of glucocorticoids is increased [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Aronson, 2009</a>].  </li></ul></li><li>The recommendation that corticosteroids should be used with caution in people with psychoses or severe affective disorders is based on the <em><em>British National Formulary</em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Joint Formulary Committee, 2020</a>], the manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">ABPI, 2020</a>], and <em>Martindale: the complete drug reference </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Brayfield, 2020</a>].  <ul><li>Systemic corticosteroids, particularly in high doses, are linked to psychiatric reactions, including euphoria, insomnia, irritability, mood lability, suicidal thoughts, psychotic reactions, and behavioural disturbances. These reactions frequently subside on reducing the dose or discontinuing the corticosteroid, but they may also require specific management [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Joint Formulary Committee, 2020</a>]. </li></ul></li><li>The recommendation that corticosteroids should be used with caution in people with wounds is pragmatic and based on the manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">ABPI, 2020</a>] and <em>Martindale: the complete drug reference </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Brayfield, 2020</a>].   <ul><li>Impaired tissue repair and immune function can lead to delayed wound healing and susceptibility to infection. Increased susceptibility to all kinds of infection, including septicaemia, tuberculosis, fungal infections, and viral infections, has been reported. Infections may also be masked by the anti-inflammatory, analgesic, and antipyretic effects of glucocorticoids [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Brayfield, 2020</a>].</li></ul></li></ul><!-- end field 46b4fa24-2c24-4703-8262-62738dd43eb7 --><!-- end item 6fc95ba9-cf03-4f33-9fed-7e8cdff16faa -->","subChapters":[]}]},{"id":"9f6a9bfb-0e7c-5d35-aca8-1a0940ebba36","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 45ca3442-9ac6-4e06-a336-060dfd296f50 --><h3>Can I prescribe oral corticosteroids to a woman who is pregnant or breastfeeding?</h3><!-- end field 45ca3442-9ac6-4e06-a336-060dfd296f50 -->","summary":null,"htmlStringContent":"<!-- begin item 8b69af62-c22d-42e3-9e1a-620517fc9d87 --><!-- begin field 1ec50d98-3c63-4a60-8b15-a038629e6d60 --><ul><li><strong>Pregnancy</strong><ul><li>Oral corticosteroids can be used in pregnancy if the benefits to the mother outweigh the risks to the child.<ul><li>The ability of different corticosteroids to cross the placental barrier varies, however, 88% of prednisolone is inactivated as it crosses the placenta.</li><li>Currently available data do not suggest that first trimester exposure to systemic corticosteroids in pregnancy increases the overall risk of congenital abnormalities, such as cleft lip/palate. </li><li>There is no robust evidence to support an association between short-term use of corticosteroids in pregnancy and intra-uterine growth retardation. However, data are limited and do not rule out adverse effects on fetal growth following repeated use, use for extended periods, or use of high-dose corticosteroids. </li><li>Any adrenal suppression in the neonate following prenatal exposure resolves spontaneously after birth and is rarely clinically important.</li></ul></li><li>Monitor pregnant women with fluid retention closely. </li></ul></li><li><strong>Breastfeeding</strong><ul><li>Prednisolone appears in small amounts in breastmilk, but maternal doses of up to 40 mg daily are unlikely to cause systemic effects in the infant. </li><li>Avoid prolonged high-dose therapy (over 40 mg daily) where possible as adrenal suppression and other adverse effects may occur in the infant, although no adverse effects have been reported. </li><li>If high doses of prednisolone are repeatedly required:<ul><li>Monitor the infant for signs of <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#adrenal-insufficiency\">adrenal insufficiency</a>. </li><li>Advise the woman that, if possible, she should wait for 4 hours after a dose before breastfeeding as this significantly reduces the dose received by the infant.</li></ul></li></ul></li></ul><!-- end field 1ec50d98-3c63-4a60-8b15-a038629e6d60 --><!-- end item 8b69af62-c22d-42e3-9e1a-620517fc9d87 -->","subChapters":[{"id":"913ccf10-62e6-52a0-bd56-be16a67b511d","slug":"basis-for-recommendation-6aa","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 8f59a084-d20b-4c0b-9519-080b1edad9ee --><h4>Basis for recommendation</h4><!-- end field 8f59a084-d20b-4c0b-9519-080b1edad9ee -->","summary":null,"htmlStringContent":"<!-- begin item 6aaafafc-bd2c-4776-9251-c2bd652ada41 --><!-- begin field dacfd1ee-51a3-4ae1-aa6b-cb8428fb4370 --><h5>Pregnancy</h5><p>These recommendations are based on the manufacturer's Summary of Product Characteristics for prednisolone tablets [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">ABPI, 2020</a>], the UK Teratology Information Service (UKTIS) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">UKTIS, 2016</a>], and the <em>British National Formulary</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Joint Formulary Committee, 2020</a>]. </p><h5>Breastfeeding</h5><p>These recommendations are based on the <em>British National Formulary</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Joint Formulary Committee, 2020</a>], a US drugs and lactation database [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">LactMed, 2018</a>], and the manufacturer's Summary of Product Characteristics for prednisolone tablets [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">ABPI, 2020</a>].</p><!-- end field dacfd1ee-51a3-4ae1-aa6b-cb8428fb4370 --><!-- end item 6aaafafc-bd2c-4776-9251-c2bd652ada41 -->","subChapters":[]}]},{"id":"edf1d5ec-ba1d-5a73-98fa-cc9ee9ff27ed","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field af60ee60-d011-492e-aea1-dcfb43a84c8e --><h3>What are the adverse effects of oral corticosteroids?</h3><!-- end field af60ee60-d011-492e-aea1-dcfb43a84c8e -->","summary":null,"htmlStringContent":"<!-- begin item b4866e8f-1e89-4e47-be01-7baa0ac35617 --><!-- begin field c5fd716b-c0eb-4111-8a3d-e69c2418bb02 --><ul><li><strong>The adverse effects of oral corticosteroids are dose related </strong>— they can often be predicted according to the mineralocorticoid and glucocorticoid <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-oral/background-information/properties-of-corticosteroids/\">properties</a>.</li><li><strong>People receiving long-term oral corticosteroids (more than 3 weeks duration) and those needing frequent courses (three or four per year) are at risk of systemic adverse effects, which are:</strong><ul><li>Cardiovascular — hypertension.</li><li>Cerebrovascular — benign intracranial hypertension.</li><li>Endocrine — adrenal suppression, diabetes mellitus (new onset or worsening of blood glucose control in existing diabetes mellitus), Cushing's syndrome (this is usually reversible on withdrawal of treatment).</li><li>Gastrointestinal — peptic ulceration with perforation and haemorrhage, dyspepsia, abdominal distension, and oesophageal ulceration; especially in <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#minimizing-adverse-effects\">high-risk people</a>.</li><li>Immunological — immunosuppression, increased susceptibility to infection, aggravation of existing infection, activation of latent infection. </li><li>Metabolic — hyperglycaemia, protein catabolism, dyslipidaemia, weight gain, sodium retention, fluid retention, potassium loss, calcium loss.</li><li>Musculoskeletal — osteoporosis, avascular necrosis of bone, tendinopathies (especially Achilles and patellar tendons).</li><li>Neurological — epidural lipomatosis, headache, vertigo.</li><li>Ophthalmic — glaucoma, cataract, central serous chorioretinopathy, blurred vision and other visual disturbances. </li><li>Psychiatric — depression, mania, euphoria, insomnia, delirium, confusion, irritability, delusions and suicidal thoughts early in treatment and especially with high doses.</li></ul></li><li><strong>Other adverse effects include:</strong><ul><li>Dysphonia.</li><li>Skin disorders — thinning of the skin, easy bruising, and delayed wound healing.</li><li>Growth impairment in children and adolescents — this may occur even after relatively small doses.</li><li>Scleroderma renal crisis – this may occur in people with systemic sclerosis and is more likely with a daily dose of 15 mg or more of prednisolone.  </li></ul></li><li>Corticosteroids may also mask the clinical signs of serious systemic disorders and infections until they have progressed to an advanced stage.</li></ul><!-- end field c5fd716b-c0eb-4111-8a3d-e69c2418bb02 --><!-- end item b4866e8f-1e89-4e47-be01-7baa0ac35617 -->","subChapters":[{"id":"3430df2f-5fe4-5415-baed-7c94ee3a6da4","slug":"adrenal-insufficiency","fullItemName":"Adrenal insufficiency","depth":4,"htmlHeader":"<!-- begin field 6e25fafa-f3ba-42ca-876f-a7a700ec7c19 --><h4>Clinical manifestation of adrenal insufficiency</h4><!-- end field 6e25fafa-f3ba-42ca-876f-a7a700ec7c19 -->","summary":null,"htmlStringContent":"<!-- begin item 8e8b34c5-9cb9-41f5-a3c6-a7a700ec79a6 --><!-- begin field bf00e465-27cb-4cfd-8d78-a7a700ec7c19 --><ul><li><strong>Adrenal insufficiency is a serious, potentially life-threatening disorder. </strong></li><li><strong>The presenting symptoms of adrenal insufficiency </strong>are non-specific and include:<ul><li>Abdominal pain, nausea, vomiting, diarrhoea.</li><li>Anorexia and weight loss (and in children, faltering growth).</li><li>Arthralgia, myalgia.</li><li>Dizziness. </li><li>Electrolyte abnormalities (hyponatraemia, hyperkalaemia), salt craving, orthostatic hypotension.</li><li>Fever.</li><li>Headache (usually in the morning).</li><li>Weakness, fatigue.</li></ul></li><li><strong>Symptoms of adrenal insufficiency can go undetected until situations trigger physiological stress, including:</strong><ul><li>Infection, trauma, and surgery.</li><li>Discontinuation of corticosteroids — a higher dose is a risk factor and longer duration and timing of administration (evening instead of morning, and daily instead of alternate days) are theoretical risks. Shorter-term use is associated with transient adrenal suppression.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Arlt, 2003</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Aronson, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Liu, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Ahmet, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Brayfield, 2020</a>]  </p><!-- end field bf00e465-27cb-4cfd-8d78-a7a700ec7c19 --><!-- end item 8e8b34c5-9cb9-41f5-a3c6-a7a700ec79a6 -->","subChapters":[]},{"id":"02008d33-2bcf-5219-8598-9567aed16d9d","slug":"basis-for-recommendation-c9f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 1fd9fa99-3fd0-4420-989e-a7a700ed20bb --><h4>Basis for recommendation</h4><!-- end field 1fd9fa99-3fd0-4420-989e-a7a700ed20bb -->","summary":null,"htmlStringContent":"<!-- begin item c9f9496e-2b09-4229-bcaa-a7a700ed1ebe --><!-- begin field f9cf6408-7ad2-43b4-b0f0-a7a700ed20bb --><p>This information is based on the manufacturer's Summary of Product Characteristics for prednisolone tablets [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">ABPI, 2020</a>], the <em>British National Formulary</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Joint Formulary Committee, 2020</a>], and the drug reference compendium <em>Martindale: the complete drug reference</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Brayfield, 2020</a>].</p><ul><li>Healthcare professionals are advised to ask patients to report any blurred vision or other visual disturbances during corticosteroid treatment; and if they occur, referral to an ophthalmologist should be considered for evaluation of possible causes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">MHRA, 2017</a>].</li></ul><!-- end field f9cf6408-7ad2-43b4-b0f0-a7a700ed20bb --><!-- end item c9f9496e-2b09-4229-bcaa-a7a700ed1ebe -->","subChapters":[]}]},{"id":"72e554a3-6fed-5620-8862-0e7c24646883","slug":"minimizing-adverse-effects","fullItemName":"Minimizing adverse effects","depth":3,"htmlHeader":"<!-- begin field 3cc66aac-b406-41d2-8636-3d7b5f213794 --><h3>How should I minimize the risks of adverse effects in people taking oral corticosteroids?</h3><!-- end field 3cc66aac-b406-41d2-8636-3d7b5f213794 -->","summary":null,"htmlStringContent":"<!-- begin item 78b726f5-8707-40f4-ba07-961506c3d042 --><!-- begin field 537f67c1-7c3f-47ce-8665-2965eeb6bff8 --><ul><li><strong>To minimize the adverse effects of oral corticosteroids:</strong><ul><li>Prescribe the lowest effective dose for the minimum possible time.</li><li>Prescribe the corticosteroid to be taken in the morning and (if the person’s condition allows it) on alternate days. This may reduce the risk, or extent, of adrenal suppression. </li><li>If the person is receiving long-term (greater than 3 weeks) treatment, provide a steroid treatment card. This gives clear guidance on the precautions to be taken to minimize the risks of adverse effects, and provides details of the prescriber, drug, dosage, and duration of treatment. </li><li>For information on minimizing the risk of osteoporosis, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/\">Osteoporosis - prevention of fragility fractures</a>.</li><li>Consider prescribing a proton pump inhibitor (PPI) for gastrointestinal protection in people at high risk of gastrointestinal bleeding or dyspepsia — PPIs are not routinely indicated for prophylaxis of peptic ulceration in people using oral corticosteroids. The risk factors for gastrointestinal adverse effects with oral corticosteroids include:<ul><li>Concomitant use of drugs that are known to increase the risk of gastrointestinal bleeding, such as nonsteroidal anti-inflammatory drugs (for example aspirin and ibuprofen) and anticoagulants. </li><li>Excessive alcohol consumption. </li><li>Heavy smoking. </li><li>History of gastroduodenal ulcer, gastrointestinal bleeding, or gastroduodenal perforation. </li><li>Older age. </li><li>Serious comorbidity, such as advanced cancer. </li></ul></li><li>Ensure that withdrawal from long-term treatment is carried out <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#withdrawal\">gradually</a> to reduce the risk of potentially fatal acute adrenal insufficiency or relapse of the condition being treated. </li><li>Be alert to the symptoms and signs of <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#adrenal-insufficiency\">adrenal insufficiency</a> and prescribe additional corticosteroid cover if stress (such as infection, trauma, or surgery) occurs.</li><li>Document the person's history of chickenpox or measles, and advise them to avoid close contact with people who have chickenpox, shingles, or measles and to seek urgent medical advice if they are exposed.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#monitoring\">Monitor</a> the person regularly for adverse effects, and manage appropriately.</li><li><strong>Note:</strong> the use of enteric-coated formulations of corticosteroid is not recommended for reducing the risk of gastrointestinal bleeding or dyspepsia. </li><li><strong>In children and adolescents:</strong><ul><li>Prescribe once daily doses on alternate days, if possible. </li><li>Long-term use of high doses should be carried out under specialist supervision.</li><li>Monitor height regularly on a growth chart.</li></ul></li></ul></li></ul><!-- end field 537f67c1-7c3f-47ce-8665-2965eeb6bff8 --><!-- end item 78b726f5-8707-40f4-ba07-961506c3d042 -->","subChapters":[{"id":"f4ca2b91-7e89-532f-ac77-711fa4aa99e9","slug":"basis-for-recommendation-a68","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 557852c6-72cc-4fee-828d-448b0b90530c --><h4>Basis for recommendation</h4><!-- end field 557852c6-72cc-4fee-828d-448b0b90530c -->","summary":null,"htmlStringContent":"<!-- begin item a680543b-5d98-4377-a964-95160728a309 --><!-- begin field a6407962-7b5e-400e-a30c-1de5ffbc7325 --><p>These recommendations are based on expert opinion in narrative reviews <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'segoe ui', Roboto, Oxygen, Ubuntu, Cantarell, 'open sans', 'helvetica neue', sans-serif;\">A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Liu, 2013</a>] and <em>Prevention and management of glucocorticoid-induced side effects: a comprehensive review: gastrointestinal and endocrinologic side effects</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Caplan, 2017b</a>], expert opinion in a textbook <em>Meyler's side effects of endocrine and metabolic drugs</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Aronson, 2009</a>], the manufacturer's Summary of Product Characteristics for prednisolone tablets [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">ABPI, 2020</a>], a drug reference compendium <em>Martindale: the complete drug reference</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Brayfield, 2020</a>], the Specialist Pharmacy Service (SPS) document <em>Is there any evidence to support the use of enteric coated (EC) over uncoated prednisolone tablets?</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">SPS, 2016</a>], and the <em>British National Formulary</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Joint Formulary Committee, 2020</a>].</p><h5>Gastrointestinal adverse effects and proton pump inhibitors (PPIs)</h5><ul><li>The recommendation that PPIs should not be prescribed routinely in people taking corticosteroids, but should be considered for gastrointestinal protection in people at high risk of gastrointestinal bleeding or dyspepsia, is based on expert opinion in narrative reviews [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Liu, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Caplan, 2017b</a>], a textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Aronson, 2009</a>], and the <em>British National Formulary</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Joint Formulary Committee, 2020</a>].<ul><li>Corticosteroid therapy is weakly linked with peptic ulceration and perforation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Joint Formulary Committee, 2020</a>].</li><li>There may be a risk of gastroduodenal ulceration, but it is no longer believed that corticosteroid treatment in adults markedly increases the risk of peptic ulceration, although the symptoms of an existing peptic ulcer can be masked [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Aronson, 2009</a>].</li><li>The risk of peptic ulcer disease due to corticosteroids alone is low, but increases significantly when they are used in combination with non-steroidal anti-inflammatory drugs (NSAIDs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Liu, 2013</a>].</li><li>Routine use of a PPI is not recommended for those taking glucocorticoids alone, but a PPI should be prescribed for people who must take a combination of glucocorticoids and NSAIDs and it can be considered in people with other risk factors for peptic ulcer disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Caplan, 2017b</a>].</li></ul></li></ul><h5>Enteric-coated preparations</h5><ul><li>There is lack of evidence to support the use of enteric-coated preparations of prednisolone to reduce the risk of peptic ulcer [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">SPS, 2016</a>]. <ul><li>However, enteric-coated preparations may be associated with less predictable absorption, which may need to be considered when switching between preparations. </li></ul></li></ul><h5>Adrenal insufficiency</h5><ul><li>The recommendations on reducing the risk, or extent, of adrenal suppression are based on the manufacturer's Summary of Product Characteristics for prednisolone tablets, expert opinion in a narrative review and the <em>British National Formulary</em>. <ul><li>Administration as a once-daily dose in the morning or on alternate days can reduce the risk of adrenocortical suppression [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">ABPI, 2020</a>].</li><li>Morning dosing is potentially less suppressive than evening doses [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Liu, 2013</a>].  </li></ul></li><li>The recommendation to prescribe additional corticosteroid cover for people taking corticosteroids who are experiencing stress is based on the <em>British National Formulary</em> and the manufacturer's summary of product characteristics for prednisolone.<ul><li>Consider additional systemic corticosteroid cover during these situations to prevent adrenal insufficiency [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Joint Formulary Committee, 2020</a>]. </li><li>During prolonged therapy, dosage may need to be temporarily increased during periods of stress or during exacerbations of the disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">ABPI, 2020</a>].</li></ul></li></ul><h5>Children and adolescents</h5><ul><li>The recommendations on the use of corticosteroids in children and adolescents are based on the manufacturer's Summary of Product Characteristics for prednisolone tablets and expert opinion in a textbook. <ul><li>Corticosteroids can cause growth suppression in infancy, childhood, and adolescence, and infants and children who are on long-term corticosteroid therapy are at particular risk of developing elevated intracranial pressure [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">ABPI, 2020</a>]. </li><li>If prolonged therapy in children is necessary, it should be limited to the minimum dose needed to treat the condition in order to minimize suppression of the hypothalamic-pituitary-adrenal axis and they should be monitored closely [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">ABPI, 2020</a>].</li><li>The use of single doses of prednisone on alternate mornings minimizes growth retardation but does not avoid it. Provided glucocorticoid treatment is terminated before the end of puberty, total growth may catch up with the physiological norm [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Aronson, 2009</a>].</li><li>The recommendation that children on long-term high doses of corticosteroids should be under the care of a specialist is pragmatic as they are at increased risk of adverse effects. </li></ul></li></ul><!-- end field a6407962-7b5e-400e-a30c-1de5ffbc7325 --><!-- end item a680543b-5d98-4377-a964-95160728a309 -->","subChapters":[]}]},{"id":"56f8e633-a8d2-588f-9abd-2db9e19b2c32","slug":"monitoring","fullItemName":"Monitoring","depth":3,"htmlHeader":"<!-- begin field fe4c73ec-febf-480b-a5f2-2c9fdd890bf4 --><h3>How do I monitor a person on oral corticosteroids?</h3><!-- end field fe4c73ec-febf-480b-a5f2-2c9fdd890bf4 -->","summary":null,"htmlStringContent":"<!-- begin item 938dc2db-2314-46da-9189-98c0cc33a956 --><!-- begin field aeafc907-4a54-455d-b8e1-7c455811fd0b --><ul><li><strong>Ensure the following baseline measurements are taken before starting treatment with long-term oral corticosteroids: </strong><ul><li>Blood pressure.</li><li>Body weight.</li><li>Body mass index (BMI).</li><li>Height (children and adolescents).</li><li>Optometrist assessment for glaucoma and cataract.</li><li>HbA1c or fasting glucose level, triglycerides, and potassium.</li></ul></li><li><strong>Ensure the following are regularly monitored during the course of corticosteroid treatment, </strong><strong>depending on clinical judgement:</strong><ul><li><strong>Blood pressure</strong> — monitor at every appointment and treat if necessary. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a>.</li><li><strong>Triglycerides and potassium</strong>  — 1 month after initiating oral corticosteroids, then every 6–12 months thereafter.</li><li><strong>HbA1c</strong> — 1 month after initiation of oral corticosteroids, and every 3 months thereafter. Monitor people with confirmed diabetes mellitus more closely, depending on clinical judgement. Oral antidiabetic drugs may need to be increased, or insulin therapy started. For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-1/\">Diabetes - type 1</a> and <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a>.</li><li><strong>Body weight</strong> — monitor regularly. Offer weight management advice if necessary. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a>.</li><li><strong>Osteoporosis risk </strong>— for information on when to prescribe prophylactic bisphosphonate therapy and when to consider arranging a dual-energy X-ray absorptiometry (DEXA) scan for people at risk of osteoporosis, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/\">Osteoporosis - prevention of fragility fractures</a>.</li><li><strong>Falls risk assessment</strong> — perform where appropriate. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/falls-risk-assessment/\">Falls - risk assessment</a>.</li><li><strong>Height of children and adolescents</strong> — measure regularly (approximately every 6 months) and plot on a growth chart. Refer to a paediatrician if growth suppression is suspected.</li><li><strong>Adrenal suppression signs </strong>— monitor people taking long-term or regular oral corticosteroids for signs of <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#adrenal-insufficiency\">adrenal insufficiency</a>. If suspected, consider biochemical testing of the hypothalamic-pituitary-adrenal (HPA) axis after steroid treatment has been reduced to a physiological dose.</li><li><strong>Eye adverse effects</strong> — arrange an eye examination every 6–12 months, but earlier for people with symptoms of cataracts. Arrange early referral for intraocular pressures assessment if personal or family history of open-angle glaucoma, diabetes, high myopia, or connective tissue disease (particularly rheumatoid arthritis).  </li><li><strong>Adverse effects </strong>— ask about <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#adverse-effects\">adverse effects</a> at every review and manage appropriately.</li></ul></li></ul><!-- end field aeafc907-4a54-455d-b8e1-7c455811fd0b --><!-- end item 938dc2db-2314-46da-9189-98c0cc33a956 -->","subChapters":[{"id":"06eb7842-3988-57e0-b3cd-3585b6a3d1bc","slug":"basis-for-recommendation-e84","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 2a9c1b87-798c-4007-9a63-f45149a707ff --><h4>Basis for recommendation</h4><!-- end field 2a9c1b87-798c-4007-9a63-f45149a707ff -->","summary":null,"htmlStringContent":"<!-- begin item e8433e9c-1d81-4c8d-b4c4-a6cb1eef3eb5 --><!-- begin field 8a8b1d71-4836-4f8f-b298-dd3aeced5ff4 --><p>These recommendations are based on the Specialist Pharmacy Service (SPS) document <em>Suggestions for drug monitoring in adults in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">SPS, 2017</a>], and expert opinion in a narrative review <em>A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Liu, 2013</a>].</p><!-- end field 8a8b1d71-4836-4f8f-b298-dd3aeced5ff4 --><!-- end item e8433e9c-1d81-4c8d-b4c4-a6cb1eef3eb5 -->","subChapters":[]}]},{"id":"ef8fe202-1138-5105-8e39-decc1c801c72","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 38b2b1b2-0fef-45c0-b5f6-0eeb507b32ea --><h3>What are the key drug interactions with oral corticosteroids?</h3><!-- end field 38b2b1b2-0fef-45c0-b5f6-0eeb507b32ea -->","summary":null,"htmlStringContent":"<!-- begin item 78dca4b8-de65-4375-813a-e4c449fdd59f --><!-- begin field bf168dea-0c2c-4024-a4eb-1c84cee889f5 --><ul><li><strong>Anticoagulants </strong>— high-dose corticosteroids can increase the anticoagulant effect of coumarins (such as warfarin) and increase the risk of gastrointestinal bleeding. Monitor the international normalized ratio (INR) with high-dose corticosteroids and consider an interaction with lower doses if there are any unexplained changes in anticoagulant control. </li><li><strong>Antiepileptics </strong>(for example, carbamazepine, phenytoin, phenobarbital)— clearance of prednisolone (and probably other glucocorticoids) is increased. Monitor the outcome of concurrent use and adjust the corticosteroid dose if necessary. </li><li><strong>Antidiabetic drugs </strong>(for example, glibenclamide, metformin, pioglitazone, sitagliptin, canagliflozin) — corticosteroids oppose the blood glucose-lowering effects of antidiabetic drugs, and significant hyperglycaemia can occur. Monitor blood glucose concentrations more closely and adjust the dose of antidiabetic treatment accordingly.</li><li><strong>Antifungals </strong>(for example, itraconazole, ketoconazole) — levels of corticosteroids may be increased, but no interaction has been established. Consider the possibility of an interaction if there is an increase in <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#adverse-effects\">adverse effects</a> of corticosteroids. </li><li><strong>Antiretroviral therapy (ART) </strong><ul><li><strong>HIV protease inhibitors </strong>— ritonavir and cobicistat increase corticosteroid concentrations. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hiv-infection-aids/\">HIV infection and AIDS</a>. If concurrent use is unavoidable, monitor for <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#adverse-effects\">adverse effects</a> of corticosteroids.<ul><li>Dexamethasone may reduce the levels of indinavir and saquinavir, and dexamethasone can cause hypokalaemia that may be additive with the effects of saquinavir boosted with ritonavir, increasing the risk of torsades de pointes — monitor potassium levels closely.</li></ul></li><li><strong>Rilpivirine </strong>— concurrent use with dexamethasone may reduce the levels of rilpivirine, and the hypokalaemia caused by dexamethasone may be additive with the effects of rilpivirine, increasing the risk of torsades de pointes. Avoid concurrent use of dexamethasone (except when given as a single dose) and monitor potassium concentrations closely.</li><li>For more information, see the website <a href=\"http://www.hiv-druginteractions.org/\" data-hyperlink-id=\"f4cae785-6c5c-4d51-98a4-a98c0138aa03\">www.hiv-druginteractions.org</a><em>.</em></li></ul></li><li><strong>Live vaccines </strong>— people immunized with live vaccines while taking immunosuppressive doses of corticosteroids (equivalent to 40 mg of prednisolone daily for more than 7 days) may develop generalized (and possibly life-threatening) infections. Live vaccines should be postponed for at least 3 months after high-dose corticosteroids are stopped. </li><li><strong>Macrolides </strong>(for example, clarithromycin, erythromycin) — levels of corticosteroids may be increased, and the risk of hypokalaemia associated with corticosteroids may be additive with effects of macrolides, further increasing the risk of torsades de pointes. Monitor potassium levels closely and reduce the dose of corticosteroid if necessary.</li><li><strong>Methotrexate </strong>— dexamethasone may increase the acute hepatotoxicity of high-dose methotrexate and accelerate the onset of severe neutropenia. If concurrent use is necessary monitor full blood count and liver function tests. </li><li><strong>Nonsteroidal anti-inflammatory drugs (NSAIDs) </strong>— NSAIDs may increase the risk of gastrointestinal bleeding and ulceration when they are given with corticosteroids. Consider the use of a proton pump inhibitor if the person is at high risk for gastrointestinal adverse effects. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/nsaids-prescribing-issues/\">NSAIDs - prescribing issues</a>. </li><li><strong>Rifampicin </strong>— rifampicin can reduce the effects of corticosteroids. Monitor the effects of concurrent use to ensure corticosteroid efficacy and adjust the dose if required.</li><li><strong>Drugs that cause hypokalaemia </strong>— corticosteroids can cause hypokalaemia that may be additive with the effects of other drugs, including: <ul><li><strong>Amitriptyline, bi</strong><strong>calutamide, chloroquine, clozapine, lithium </strong>— monitor potassium levels closely. </li><li><strong>Bronchodilators </strong>(for example, salbutamol) — consider monitoring potassium levels based on the severity of the person's condition and the number of potassium-depleting drugs used. </li><li><strong>Digoxin </strong>— monitor concurrent use for digoxin adverse effects (for example, bradycardia) and consider monitoring potassium levels. </li><li><strong>Diuretics </strong>(for example, furosemide, hydrochlorothiazide) — monitor potassium levels and supplement if necessary.</li></ul></li></ul><!-- end field bf168dea-0c2c-4024-a4eb-1c84cee889f5 --><!-- end item 78dca4b8-de65-4375-813a-e4c449fdd59f -->","subChapters":[{"id":"9f7122be-ae48-5a98-88f3-af3f3c55cec6","slug":"basis-for-recommendation-d99","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 00a929c4-9c56-4642-9de6-b76187463d88 --><h4>Basis for recommendation</h4><!-- end field 00a929c4-9c56-4642-9de6-b76187463d88 -->","summary":null,"htmlStringContent":"<!-- begin item d99aec2f-acb5-4fc8-ba4a-1f49551dcbd9 --><!-- begin field 014f29d2-fc8a-4801-aae6-31d770413069 --><p>These recommendations are based on the textbook <em>Stockley's drug interactions </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Preston, 2020</a>].</p><!-- end field 014f29d2-fc8a-4801-aae6-31d770413069 --><!-- end item d99aec2f-acb5-4fc8-ba4a-1f49551dcbd9 -->","subChapters":[]}]},{"id":"3b8b37ac-62ab-5c38-b45a-3dcb5d731c6c","slug":"withdrawal","fullItemName":"Withdrawal","depth":3,"htmlHeader":"<!-- begin field 427c6ed1-bd28-436c-8dd7-71f8c470f5ed --><h3>How should I withdraw or stop oral corticosteroid treatment?</h3><!-- end field 427c6ed1-bd28-436c-8dd7-71f8c470f5ed -->","summary":null,"htmlStringContent":"<!-- begin item c36eaa2f-f9ab-4a49-9dcb-20a9176f5528 --><!-- begin field af479da4-e72e-41b7-95d8-2b02b8416441 --><ul><li>Owing to insufficient evidence to support any particular withdrawal regimen, the rate of withdrawal should depend on:<ul><li>The person's response to the withdrawal (if <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#adrenal-insufficiency\">withdrawal symptoms</a> are reported, resume a higher dose and continue the withdrawal at a slower rate). </li><li>The disease being treated.</li><li>The duration of treatment and dosage.</li></ul></li><li>As a general principle:<ul><li><strong>Short courses </strong>of oral corticosteroids (less than 3 weeks) can be stopped abruptly. </li><li><strong>Gradual withdrawal </strong>should be considered for people whose disease is unlikely to relapse and who have: <ul><li>Received more than 40 mg prednisolone daily or <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-oral/background-information/equivalent-anti-inflammatory-doses/\">equivalent</a> for more than 1 week.</li><li>Been taking repeated evening doses of corticosteroids, which increases the risks of developing <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#adrenal-insufficiency\">adrenal insufficiency</a>.</li><li>Received more than 3 weeks of corticosteroid treatment.</li><li>Recently received repeated courses of corticosteroids (especially if they have been taken for longer than 3 weeks), for example prescribed for the treatment of acute exacerbations of asthma.</li><li>A history of previous long-term therapy (months or years).</li><li>Other possible causes of adrenal suppression, such as excessive alcohol consumption or stress (for example due to infection, trauma, or surgery).</li></ul></li></ul></li><li>If stress, for example caused by infection, trauma, or surgery, occurs up to 1 week after stopping the corticosteroid, additional corticosteroid cover should be prescribed to compensate for any potential adrenal suppression. </li><li>During withdrawal, the dose of oral corticosteroids may be reduced rapidly down to physiological doses (about 7.5 mg of prednisolone or <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-oral/background-information/equivalent-anti-inflammatory-doses/\">equivalent</a>) and reduced more slowly thereafter. For a suggested withdrawal regime of oral prednisolone, see Table 3.</li></ul><p><strong>Table 3.</strong> Suggested method of withdrawing prednisolone.</p><table data-table-id=\"cef54095-5961-4494-a3c2-acce014ef304\"><thead><tr><th colspan=\"1\">Circumstance</th><th colspan=\"1\">Suggested change in daily dose</th></tr></thead><tbody><tr><td colspan=\"1\">The problem has resolved and treatment has been given for only a few weeks.</td><td colspan=\"1\">Reduce by 2.5 mg every 3–4 days, down to 7.5 mg per day, then reduce more slowly, for example by 2.5 mg every week, fortnight, or month.</td></tr><tr><td colspan=\"1\">There is uncertainty about disease resolution and/or therapy has been given for many weeks.</td><td colspan=\"1\">Reduce by 2.5 mg every fortnight or month down to 7.5 mg per day, then reduce by 1 mg every month.</td></tr><tr><td colspan=\"1\">Symptoms of the disease are likely to recur on withdrawal (for example polymyalgia rheumatica [PMR]).</td><td colspan=\"1\">Reduce by 1 mg every month. Alternatively, the withdrawal regimen may be more complex, for example in the treatment of PMR – see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/polymyalgia-rheumatica/\">Polymyalgia rheumatica</a> for more information.</td></tr><tr><td colspan=\"2\">Data from [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Aronson, 2009</a>]</td></tr></tbody></table><!-- end field af479da4-e72e-41b7-95d8-2b02b8416441 --><!-- end item c36eaa2f-f9ab-4a49-9dcb-20a9176f5528 -->","subChapters":[{"id":"8a888782-e8f5-5c42-9fe4-f8b07514ba7f","slug":"basis-for-recommendation-e87","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a3d33416-6c32-42b7-a72c-27a0433888f4 --><h4>Basis for recommendation</h4><!-- end field a3d33416-6c32-42b7-a72c-27a0433888f4 -->","summary":null,"htmlStringContent":"<!-- begin item e87d9ada-6064-452e-9f9e-31b5aa1e67f6 --><!-- begin field f17ddea0-2ed0-4619-b9d0-34c9628b4f2d --><p>These recommendations are based on the <em>British National Formulary</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Joint Formulary Committee, 2020</a>], a drug reference compendium <em>Martindale: the complete drug reference</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Brayfield, 2020</a>], expert opinion in a textbook <em>Meyler's side effects of endocrine and metabolic drugs</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Aronson, 2009</a>], expert opinion in narrative reviews <em>A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Liu, 2013</a>] and <em>Adrenal suppression from glucocorticoids: preventing an iatrogenic cause of morbidity and mortality in children</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Ahmet, 2019</a>], and the manufacturer's Summary of Product Characteristics for prednisolone tablets [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">ABPI, 2020</a>].</p><ul><li>Rapid withdrawal of long-term (more than 3 weeks) treatment with an oral corticosteroid may cause acute adrenal insufficiency (which can be fatal) and/or a relapse of the underlying condition [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Joint Formulary Committee, 2020</a>].</li><li>There is a lack of evidence to support specific withdrawal regimens, although whichever regime is used, clinicians should be aware of the symptoms of adrenal suppression [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Liu, 2013</a>].</li><li>There is no evidence to support a specific approach to tapering glucocorticoids for the prevention of adrenal suppression — a gradual taper does not prevent it [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Ahmet, 2019</a>].<ul><li>Glucocorticoids should be tapered or discontinued at a rate dictated by the underlying condition in order to maintain disease remission; if not indicated for prevention of disease relapse, a prolonged taper should be avoided to prevent unnecessary glucocorticoid exposure.</li></ul></li><li>Significant suppression is likely in people receiving more than 3 weeks of therapy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Brayfield, 2020</a>], however, the manufacturer recommends that gradual withdrawal of prednisolone should be considered even after courses lasting 3 weeks or less [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">ABPI, 2020</a>]:<ul><li>In people who have had repeated courses of systemic corticosteroids, particularly if taken for greater than 3 weeks.</li><li>When a short course has been prescribed within 1 year of cessation of long-term therapy (months or years).</li><li>In people who may have reasons for adrenocortical insufficiency other than exogenous corticosteroid therapy.</li><li>In people receiving doses of systemic corticosteroid greater than 40 mg daily of prednisolone (or equivalent).</li><li>In people repeatedly taking doses in the evening.</li></ul></li></ul><!-- end field f17ddea0-2ed0-4619-b9d0-34c9628b4f2d --><!-- end item e87d9ada-6064-452e-9f9e-31b5aa1e67f6 -->","subChapters":[]}]},{"id":"b52ea19f-04d7-5c31-87d3-7df15a8433bf","slug":"information-advice","fullItemName":"Information and advice","depth":3,"htmlHeader":"<!-- begin field e97547ca-aef6-4357-ae27-b8092a684dc8 --><h3>What information and advice should I give to a person receiving oral corticosteroids?</h3><!-- end field e97547ca-aef6-4357-ae27-b8092a684dc8 -->","summary":null,"htmlStringContent":"<!-- begin item 03966041-7c46-45c0-98e1-cf71ff670a01 --><!-- begin field 53acbd4e-87e8-4cde-bf42-423cc909f454 --><ul><li><strong>Provide information about: </strong><ul><li>Possible <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#adverse-effects\">adverse effects</a> of corticosteroids.</li><li>The regular <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#monitoring\">monitoring</a> required (for example, an eye examination every 6–12 months).</li></ul></li><li><strong>Advise the person receiving oral corticosteroids to:</strong><ul><li>Take it as a single dose in the morning, with food.</li><li>Avoid contact with people that have shingles, chickenpox, or measles (unless, according to clinical judgment, the person being treated is assessed as having immunity to these conditions) — if they come into contact with these people, they must seek urgent medical advice.</li><li>Be aware of any mood or behavioural changes, and seek medical advice if they become confused, irritable, or have suicidal thoughts.</li><li>Be aware of the symptoms of <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#adrenal-insufficiency\">adrenal insufficiency</a>, and seek immediate medical attention if they experience them. </li><li>Continue taking their medication — they must not stop abruptly unless advised to do so.</li><li>Adopt lifestyle measures to reduce the risk of adverse effects: <ul><li>Eat a healthy balanced diet, including adequate calcium intake (see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/\">Osteoporosis - prevention of fragility fractures</a>).</li><li>Maintain a normal body weight if possible (see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a>).</li><li>Stop smoking if possible (see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a>).</li><li>Drink alcohol in moderation (see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/alcohol-problem-drinking/\">Alcohol - problem drinking</a>).</li><li>Take physical exercise — within the limits imposed by the underlying disease (see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a>).</li></ul></li><li>Carry a steroid treatment card if they are receiving long-term treatment (more than 3 weeks) and/or high doses. <ul><li>This provides clear guidance on the precautions to be taken to minimize the risks of adverse effects, and provides details of the prescriber, drug, dosage, and the duration of treatment.</li><li>GP practices can obtain supplies through Primary Care Support England. </li></ul></li></ul></li><li><strong>COVID-19</strong><ul><li>The advice for people taking long-term oral steroids for any indication is to continue at the prescribed dose in order to optimise the control of their condition.</li></ul></li></ul><!-- end field 53acbd4e-87e8-4cde-bf42-423cc909f454 --><!-- end item 03966041-7c46-45c0-98e1-cf71ff670a01 -->","subChapters":[{"id":"08b5160a-f3b1-578b-864a-17e92a8083a7","slug":"basis-for-recommendation-f58","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field c1f8394a-6a4e-43ca-bd75-ff0d328cd314 --><h4>Basis for recommendation</h4><!-- end field c1f8394a-6a4e-43ca-bd75-ff0d328cd314 -->","summary":null,"htmlStringContent":"<!-- begin item f587430f-c80e-4a17-a662-121946a208c2 --><!-- begin field 6e65458e-944d-4507-977e-94b5de3b8e65 --><p>These recommendations are based on the manufacturer's Summary of Product Characteristics for prednisolone tablets [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">ABPI, 2020</a>], the <em>British National Formulary</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Joint Formulary Committee, 2020</a>], and expert opinion in a narrative review <em>A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Liu, 2013</a>].</p><ul><li>The recommendation to not stop taking oral steroids during the COVID-19 pandemic is based on the National Institute for Health and Care Excellence (NICE) rapid guidelines <em>COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD</em>) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">NICE, 2020a</a>], <em>COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">NICE, 2020b</a>], and<em> COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">NICE, 2020c</a>]. </li></ul><!-- end field 6e65458e-944d-4507-977e-94b5de3b8e65 --><!-- end item f587430f-c80e-4a17-a662-121946a208c2 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}